nodes	percent_of_prediction	percent_of_DWPC	metapath
Mirabegron—BCHE—multiple sclerosis	0.335	0.709	CbGaD
Mirabegron—ALB—multiple sclerosis	0.138	0.291	CbGaD
Mirabegron—BCHE—Triamcinolone—multiple sclerosis	0.061	0.137	CbGbCtD
Mirabegron—SLCO1A2—Prednisolone—multiple sclerosis	0.0485	0.109	CbGbCtD
Mirabegron—SLCO1A2—Prednisone—multiple sclerosis	0.0458	0.103	CbGbCtD
Mirabegron—CYP2D6—Fingolimod—multiple sclerosis	0.0299	0.0672	CbGbCtD
Mirabegron—SLCO1A2—Dexamethasone—multiple sclerosis	0.0286	0.0643	CbGbCtD
Mirabegron—ALB—Prednisone—multiple sclerosis	0.0237	0.0532	CbGbCtD
Mirabegron—SLCO1A2—Methotrexate—multiple sclerosis	0.023	0.0517	CbGbCtD
Mirabegron—ABCB1—Methylprednisolone—multiple sclerosis	0.0204	0.0459	CbGbCtD
Mirabegron—CYP3A4—Fingolimod—multiple sclerosis	0.019	0.0427	CbGbCtD
Mirabegron—ABCB1—Mitoxantrone—multiple sclerosis	0.0149	0.0335	CbGbCtD
Mirabegron—ABCB1—Betamethasone—multiple sclerosis	0.0133	0.0299	CbGbCtD
Mirabegron—ABCB1—Prednisolone—multiple sclerosis	0.0131	0.0295	CbGbCtD
Mirabegron—ABCB1—Prednisone—multiple sclerosis	0.0124	0.0278	CbGbCtD
Mirabegron—CYP3A4—Methylprednisolone—multiple sclerosis	0.0122	0.0275	CbGbCtD
Mirabegron—ALB—Methotrexate—multiple sclerosis	0.0119	0.0267	CbGbCtD
Mirabegron—CYP3A4—Triamcinolone—multiple sclerosis	0.00928	0.0209	CbGbCtD
Mirabegron—CYP3A4—Mitoxantrone—multiple sclerosis	0.00893	0.0201	CbGbCtD
Mirabegron—CYP3A4—Betamethasone—multiple sclerosis	0.00796	0.0179	CbGbCtD
Mirabegron—CYP3A4—Prednisolone—multiple sclerosis	0.00785	0.0177	CbGbCtD
Mirabegron—ABCB1—Dexamethasone—multiple sclerosis	0.00773	0.0174	CbGbCtD
Mirabegron—CYP3A4—Prednisone—multiple sclerosis	0.00742	0.0167	CbGbCtD
Mirabegron—CYP2D6—Dexamethasone—multiple sclerosis	0.00728	0.0164	CbGbCtD
Mirabegron—ABCB1—Methotrexate—multiple sclerosis	0.00621	0.014	CbGbCtD
Mirabegron—CYP3A4—Dexamethasone—multiple sclerosis	0.00463	0.0104	CbGbCtD
Mirabegron—Glaucoma—Prednisone—multiple sclerosis	0.000465	0.00613	CcSEcCtD
Mirabegron—Urinary tract disorder—Cladribine—multiple sclerosis	0.000443	0.00584	CcSEcCtD
Mirabegron—Connective tissue disorder—Cladribine—multiple sclerosis	0.000441	0.00581	CcSEcCtD
Mirabegron—Urethral disorder—Cladribine—multiple sclerosis	0.00044	0.0058	CcSEcCtD
Mirabegron—Erythema multiforme—Cladribine—multiple sclerosis	0.000424	0.0056	CcSEcCtD
Mirabegron—Eye disorder—Cladribine—multiple sclerosis	0.000419	0.00553	CcSEcCtD
Mirabegron—Cardiac disorder—Cladribine—multiple sclerosis	0.000416	0.00549	CcSEcCtD
Mirabegron—Infestation NOS—Azathioprine—multiple sclerosis	0.000406	0.00536	CcSEcCtD
Mirabegron—Infestation—Azathioprine—multiple sclerosis	0.000406	0.00536	CcSEcCtD
Mirabegron—Asthenia—Fingolimod—multiple sclerosis	0.000403	0.00532	CcSEcCtD
Mirabegron—Stevens-Johnson syndrome—Azathioprine—multiple sclerosis	0.000403	0.00531	CcSEcCtD
Mirabegron—Pruritus—Fingolimod—multiple sclerosis	0.000398	0.00525	CcSEcCtD
Mirabegron—Diarrhoea—Fingolimod—multiple sclerosis	0.000385	0.00507	CcSEcCtD
Mirabegron—Aspartate aminotransferase increased—Mitoxantrone—multiple sclerosis	0.000384	0.00506	CcSEcCtD
Mirabegron—Back pain—Cladribine—multiple sclerosis	0.000378	0.00498	CcSEcCtD
Mirabegron—Alanine aminotransferase increased—Mitoxantrone—multiple sclerosis	0.000376	0.00496	CcSEcCtD
Mirabegron—Dizziness—Fingolimod—multiple sclerosis	0.000372	0.0049	CcSEcCtD
Mirabegron—Dry eye—Dexamethasone—multiple sclerosis	0.000371	0.0049	CcSEcCtD
Mirabegron—Dry eye—Betamethasone—multiple sclerosis	0.000371	0.0049	CcSEcCtD
Mirabegron—Vascular purpura—Triamcinolone—multiple sclerosis	0.00036	0.00474	CcSEcCtD
Mirabegron—Headache—Fingolimod—multiple sclerosis	0.000352	0.00465	CcSEcCtD
Mirabegron—Osteoarthritis—Prednisolone—multiple sclerosis	0.00035	0.00461	CcSEcCtD
Mirabegron—Erythema multiforme—Azathioprine—multiple sclerosis	0.000345	0.00455	CcSEcCtD
Mirabegron—Upper respiratory tract infection—Mitoxantrone—multiple sclerosis	0.000342	0.00452	CcSEcCtD
Mirabegron—Purpura—Triamcinolone—multiple sclerosis	0.000334	0.0044	CcSEcCtD
Mirabegron—Arthralgia—Cladribine—multiple sclerosis	0.000332	0.00439	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Cladribine—multiple sclerosis	0.00033	0.00436	CcSEcCtD
Mirabegron—Osteoarthritis—Triamcinolone—multiple sclerosis	0.000322	0.00424	CcSEcCtD
Mirabegron—Osteoarthritis—Methylprednisolone—multiple sclerosis	0.000321	0.00423	CcSEcCtD
Mirabegron—Urinary tract infection—Mitoxantrone—multiple sclerosis	0.000319	0.00421	CcSEcCtD
Mirabegron—Infection—Cladribine—multiple sclerosis	0.000317	0.00418	CcSEcCtD
Mirabegron—Tachycardia—Cladribine—multiple sclerosis	0.000311	0.0041	CcSEcCtD
Mirabegron—Skin disorder—Cladribine—multiple sclerosis	0.00031	0.00408	CcSEcCtD
Mirabegron—Sinusitis—Mitoxantrone—multiple sclerosis	0.000308	0.00406	CcSEcCtD
Mirabegron—Abdominal distension—Prednisolone—multiple sclerosis	0.000304	0.00401	CcSEcCtD
Mirabegron—Rhinitis—Mitoxantrone—multiple sclerosis	0.000296	0.0039	CcSEcCtD
Mirabegron—Osteoarthritis—Betamethasone—multiple sclerosis	0.000292	0.00385	CcSEcCtD
Mirabegron—Osteoarthritis—Dexamethasone—multiple sclerosis	0.000292	0.00385	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Cladribine—multiple sclerosis	0.00029	0.00383	CcSEcCtD
Mirabegron—Breast disorder—Methylprednisolone—multiple sclerosis	0.00029	0.00382	CcSEcCtD
Mirabegron—Cystitis noninfective—Methotrexate—multiple sclerosis	0.000286	0.00377	CcSEcCtD
Mirabegron—Vascular purpura—Prednisone—multiple sclerosis	0.000284	0.00375	CcSEcCtD
Mirabegron—Alanine aminotransferase increased—Methylprednisolone—multiple sclerosis	0.000283	0.00373	CcSEcCtD
Mirabegron—Cystitis—Methotrexate—multiple sclerosis	0.000283	0.00373	CcSEcCtD
Mirabegron—Abdominal distension—Triamcinolone—multiple sclerosis	0.00028	0.00369	CcSEcCtD
Mirabegron—Abdominal distension—Methylprednisolone—multiple sclerosis	0.000279	0.00368	CcSEcCtD
Mirabegron—Influenza—Triamcinolone—multiple sclerosis	0.000278	0.00367	CcSEcCtD
Mirabegron—Vaginal infection—Methotrexate—multiple sclerosis	0.000276	0.00364	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Cladribine—multiple sclerosis	0.000275	0.00363	CcSEcCtD
Mirabegron—Fatigue—Cladribine—multiple sclerosis	0.000275	0.00362	CcSEcCtD
Mirabegron—Constipation—Cladribine—multiple sclerosis	0.000273	0.0036	CcSEcCtD
Mirabegron—Arthralgia—Azathioprine—multiple sclerosis	0.00027	0.00357	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—multiple sclerosis	0.000268	0.00354	CcSEcCtD
Mirabegron—Bladder pain—Methotrexate—multiple sclerosis	0.000265	0.00349	CcSEcCtD
Mirabegron—Neoplasm—Methotrexate—multiple sclerosis	0.000265	0.00349	CcSEcCtD
Mirabegron—Purpura—Prednisone—multiple sclerosis	0.000264	0.00348	CcSEcCtD
Mirabegron—Gastrointestinal pain—Cladribine—multiple sclerosis	0.000261	0.00344	CcSEcCtD
Mirabegron—Upper respiratory tract infection—Triamcinolone—multiple sclerosis	0.000258	0.00341	CcSEcCtD
Mirabegron—Infection—Azathioprine—multiple sclerosis	0.000257	0.0034	CcSEcCtD
Mirabegron—Osteoarthritis—Prednisone—multiple sclerosis	0.000254	0.00335	CcSEcCtD
Mirabegron—Urticaria—Cladribine—multiple sclerosis	0.000253	0.00334	CcSEcCtD
Mirabegron—Abdominal pain—Cladribine—multiple sclerosis	0.000252	0.00332	CcSEcCtD
Mirabegron—Skin disorder—Azathioprine—multiple sclerosis	0.000252	0.00332	CcSEcCtD
Mirabegron—Back pain—Mitoxantrone—multiple sclerosis	0.000248	0.00328	CcSEcCtD
Mirabegron—Infestation NOS—Methylprednisolone—multiple sclerosis	0.000247	0.00326	CcSEcCtD
Mirabegron—Infestation—Methylprednisolone—multiple sclerosis	0.000247	0.00326	CcSEcCtD
Mirabegron—Vision blurred—Mitoxantrone—multiple sclerosis	0.000242	0.00319	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Azathioprine—multiple sclerosis	0.000236	0.00311	CcSEcCtD
Mirabegron—Asthenia—Cladribine—multiple sclerosis	0.000229	0.00302	CcSEcCtD
Mirabegron—Pruritus—Cladribine—multiple sclerosis	0.000226	0.00297	CcSEcCtD
Mirabegron—Alanine aminotransferase increased—Prednisone—multiple sclerosis	0.000224	0.00296	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Azathioprine—multiple sclerosis	0.000224	0.00295	CcSEcCtD
Mirabegron—Rhinitis—Triamcinolone—multiple sclerosis	0.000223	0.00294	CcSEcCtD
Mirabegron—Rhinitis—Methylprednisolone—multiple sclerosis	0.000223	0.00294	CcSEcCtD
Mirabegron—Hypertension—Mitoxantrone—multiple sclerosis	0.000222	0.00292	CcSEcCtD
Mirabegron—Abdominal distension—Prednisone—multiple sclerosis	0.000221	0.00292	CcSEcCtD
Mirabegron—Arthralgia—Mitoxantrone—multiple sclerosis	0.000219	0.00288	CcSEcCtD
Mirabegron—Connective tissue disorder—Methylprednisolone—multiple sclerosis	0.000218	0.00288	CcSEcCtD
Mirabegron—Diarrhoea—Cladribine—multiple sclerosis	0.000218	0.00288	CcSEcCtD
Mirabegron—Cerebrovascular accident—Methotrexate—multiple sclerosis	0.000217	0.00286	CcSEcCtD
Mirabegron—Osteoarthritis—Methotrexate—multiple sclerosis	0.000212	0.0028	CcSEcCtD
Mirabegron—Gastrointestinal pain—Azathioprine—multiple sclerosis	0.000212	0.0028	CcSEcCtD
Mirabegron—Dizziness—Cladribine—multiple sclerosis	0.000211	0.00278	CcSEcCtD
Mirabegron—Infection—Mitoxantrone—multiple sclerosis	0.000208	0.00275	CcSEcCtD
Mirabegron—Eye disorder—Methylprednisolone—multiple sclerosis	0.000207	0.00274	CcSEcCtD
Mirabegron—Cardiac disorder—Methylprednisolone—multiple sclerosis	0.000206	0.00272	CcSEcCtD
Mirabegron—Abdominal pain—Azathioprine—multiple sclerosis	0.000205	0.0027	CcSEcCtD
Mirabegron—Tachycardia—Mitoxantrone—multiple sclerosis	0.000204	0.0027	CcSEcCtD
Mirabegron—Skin disorder—Mitoxantrone—multiple sclerosis	0.000204	0.00268	CcSEcCtD
Mirabegron—Rash—Cladribine—multiple sclerosis	0.000201	0.00265	CcSEcCtD
Mirabegron—Dermatitis—Cladribine—multiple sclerosis	0.000201	0.00265	CcSEcCtD
Mirabegron—Headache—Cladribine—multiple sclerosis	0.0002	0.00263	CcSEcCtD
Mirabegron—Vision blurred—Prednisolone—multiple sclerosis	0.000198	0.00262	CcSEcCtD
Mirabegron—Breast disorder—Methotrexate—multiple sclerosis	0.000192	0.00253	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Mitoxantrone—multiple sclerosis	0.000191	0.00252	CcSEcCtD
Mirabegron—Nausea—Cladribine—multiple sclerosis	0.000189	0.0025	CcSEcCtD
Mirabegron—Eye disorder—Dexamethasone—multiple sclerosis	0.000189	0.00249	CcSEcCtD
Mirabegron—Eye disorder—Betamethasone—multiple sclerosis	0.000189	0.00249	CcSEcCtD
Mirabegron—Back pain—Triamcinolone—multiple sclerosis	0.000187	0.00247	CcSEcCtD
Mirabegron—Dyspepsia—Mitoxantrone—multiple sclerosis	0.000184	0.00243	CcSEcCtD
Mirabegron—Hypertension—Prednisolone—multiple sclerosis	0.000182	0.0024	CcSEcCtD
Mirabegron—Fatigue—Mitoxantrone—multiple sclerosis	0.000181	0.00238	CcSEcCtD
Mirabegron—Constipation—Mitoxantrone—multiple sclerosis	0.000179	0.00236	CcSEcCtD
Mirabegron—Diarrhoea—Azathioprine—multiple sclerosis	0.000177	0.00234	CcSEcCtD
Mirabegron—Connective tissue disorder—Prednisone—multiple sclerosis	0.000173	0.00228	CcSEcCtD
Mirabegron—Dizziness—Azathioprine—multiple sclerosis	0.000171	0.00226	CcSEcCtD
Mirabegron—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.000171	0.00226	CcSEcCtD
Mirabegron—Upper respiratory tract infection—Methotrexate—multiple sclerosis	0.000171	0.00225	CcSEcCtD
Mirabegron—Tachycardia—Prednisolone—multiple sclerosis	0.000168	0.00221	CcSEcCtD
Mirabegron—Hypertension—Triamcinolone—multiple sclerosis	0.000167	0.00221	CcSEcCtD
Mirabegron—Hypertension—Methylprednisolone—multiple sclerosis	0.000167	0.0022	CcSEcCtD
Mirabegron—Urticaria—Mitoxantrone—multiple sclerosis	0.000166	0.0022	CcSEcCtD
Mirabegron—Abdominal pain—Mitoxantrone—multiple sclerosis	0.000166	0.00218	CcSEcCtD
Mirabegron—Arthralgia—Methylprednisolone—multiple sclerosis	0.000165	0.00217	CcSEcCtD
Mirabegron—Eye disorder—Prednisone—multiple sclerosis	0.000164	0.00217	CcSEcCtD
Mirabegron—Infestation NOS—Methotrexate—multiple sclerosis	0.000164	0.00216	CcSEcCtD
Mirabegron—Infestation—Methotrexate—multiple sclerosis	0.000164	0.00216	CcSEcCtD
Mirabegron—Rash—Azathioprine—multiple sclerosis	0.000163	0.00216	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000163	0.00216	CcSEcCtD
Mirabegron—Dermatitis—Azathioprine—multiple sclerosis	0.000163	0.00215	CcSEcCtD
Mirabegron—Headache—Azathioprine—multiple sclerosis	0.000162	0.00214	CcSEcCtD
Mirabegron—Stevens-Johnson syndrome—Methotrexate—multiple sclerosis	0.000162	0.00214	CcSEcCtD
Mirabegron—Dry mouth—Triamcinolone—multiple sclerosis	0.000161	0.00213	CcSEcCtD
Mirabegron—Infection—Triamcinolone—multiple sclerosis	0.000157	0.00207	CcSEcCtD
Mirabegron—Infection—Methylprednisolone—multiple sclerosis	0.000157	0.00207	CcSEcCtD
Mirabegron—Tachycardia—Triamcinolone—multiple sclerosis	0.000154	0.00203	CcSEcCtD
Mirabegron—Nausea—Azathioprine—multiple sclerosis	0.000154	0.00203	CcSEcCtD
Mirabegron—Tachycardia—Methylprednisolone—multiple sclerosis	0.000154	0.00203	CcSEcCtD
Mirabegron—Skin disorder—Methylprednisolone—multiple sclerosis	0.000153	0.00202	CcSEcCtD
Mirabegron—Hypertension—Dexamethasone—multiple sclerosis	0.000152	0.002	CcSEcCtD
Mirabegron—Hypertension—Betamethasone—multiple sclerosis	0.000152	0.002	CcSEcCtD
Mirabegron—Asthenia—Mitoxantrone—multiple sclerosis	0.00015	0.00198	CcSEcCtD
Mirabegron—Urinary tract disorder—Methotrexate—multiple sclerosis	0.000145	0.00191	CcSEcCtD
Mirabegron—Vision blurred—Prednisone—multiple sclerosis	0.000144	0.0019	CcSEcCtD
Mirabegron—Urethral disorder—Methotrexate—multiple sclerosis	0.000144	0.0019	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.000144	0.0019	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000144	0.0019	CcSEcCtD
Mirabegron—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000143	0.00189	CcSEcCtD
Mirabegron—Infection—Betamethasone—multiple sclerosis	0.000142	0.00188	CcSEcCtD
Mirabegron—Infection—Dexamethasone—multiple sclerosis	0.000142	0.00188	CcSEcCtD
Mirabegron—Tachycardia—Betamethasone—multiple sclerosis	0.00014	0.00185	CcSEcCtD
Mirabegron—Tachycardia—Dexamethasone—multiple sclerosis	0.00014	0.00185	CcSEcCtD
Mirabegron—Dyspepsia—Triamcinolone—multiple sclerosis	0.000139	0.00184	CcSEcCtD
Mirabegron—Erythema multiforme—Methotrexate—multiple sclerosis	0.000139	0.00183	CcSEcCtD
Mirabegron—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000139	0.00183	CcSEcCtD
Mirabegron—Eye disorder—Methotrexate—multiple sclerosis	0.000137	0.00181	CcSEcCtD
Mirabegron—Urticaria—Prednisolone—multiple sclerosis	0.000137	0.0018	CcSEcCtD
Mirabegron—Cardiac disorder—Methotrexate—multiple sclerosis	0.000136	0.0018	CcSEcCtD
Mirabegron—Fatigue—Triamcinolone—multiple sclerosis	0.000136	0.0018	CcSEcCtD
Mirabegron—Fatigue—Methylprednisolone—multiple sclerosis	0.000136	0.00179	CcSEcCtD
Mirabegron—Hypertension—Prednisone—multiple sclerosis	0.000132	0.00174	CcSEcCtD
Mirabegron—Rash—Mitoxantrone—multiple sclerosis	0.000132	0.00174	CcSEcCtD
Mirabegron—Dermatitis—Mitoxantrone—multiple sclerosis	0.000132	0.00174	CcSEcCtD
Mirabegron—Headache—Mitoxantrone—multiple sclerosis	0.000131	0.00173	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000131	0.00172	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000131	0.00172	CcSEcCtD
Mirabegron—Arthralgia—Prednisone—multiple sclerosis	0.00013	0.00172	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000129	0.00171	CcSEcCtD
Mirabegron—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000129	0.0017	CcSEcCtD
Mirabegron—Dyspepsia—Betamethasone—multiple sclerosis	0.000126	0.00167	CcSEcCtD
Mirabegron—Dyspepsia—Dexamethasone—multiple sclerosis	0.000126	0.00167	CcSEcCtD
Mirabegron—Urticaria—Triamcinolone—multiple sclerosis	0.000126	0.00166	CcSEcCtD
Mirabegron—Urticaria—Methylprednisolone—multiple sclerosis	0.000125	0.00165	CcSEcCtD
Mirabegron—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000125	0.00164	CcSEcCtD
Mirabegron—Nausea—Mitoxantrone—multiple sclerosis	0.000124	0.00164	CcSEcCtD
Mirabegron—Infection—Prednisone—multiple sclerosis	0.000124	0.00164	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000124	0.00163	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000124	0.00163	CcSEcCtD
Mirabegron—Back pain—Methotrexate—multiple sclerosis	0.000124	0.00163	CcSEcCtD
Mirabegron—Fatigue—Betamethasone—multiple sclerosis	0.000124	0.00163	CcSEcCtD
Mirabegron—Fatigue—Dexamethasone—multiple sclerosis	0.000124	0.00163	CcSEcCtD
Mirabegron—Tachycardia—Prednisone—multiple sclerosis	0.000122	0.00161	CcSEcCtD
Mirabegron—Skin disorder—Prednisone—multiple sclerosis	0.000121	0.0016	CcSEcCtD
Mirabegron—Vision blurred—Methotrexate—multiple sclerosis	0.000121	0.00159	CcSEcCtD
Mirabegron—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000117	0.00155	CcSEcCtD
Mirabegron—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000117	0.00155	CcSEcCtD
Mirabegron—Urticaria—Betamethasone—multiple sclerosis	0.000114	0.0015	CcSEcCtD
Mirabegron—Urticaria—Dexamethasone—multiple sclerosis	0.000114	0.0015	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.000114	0.0015	CcSEcCtD
Mirabegron—Dizziness—Prednisolone—multiple sclerosis	0.000114	0.0015	CcSEcCtD
Mirabegron—Asthenia—Triamcinolone—multiple sclerosis	0.000113	0.0015	CcSEcCtD
Mirabegron—Abdominal pain—Betamethasone—multiple sclerosis	0.000113	0.0015	CcSEcCtD
Mirabegron—Abdominal pain—Dexamethasone—multiple sclerosis	0.000113	0.0015	CcSEcCtD
Mirabegron—Asthenia—Methylprednisolone—multiple sclerosis	0.000113	0.00149	CcSEcCtD
Mirabegron—Pruritus—Triamcinolone—multiple sclerosis	0.000112	0.00148	CcSEcCtD
Mirabegron—Pruritus—Methylprednisolone—multiple sclerosis	0.000112	0.00147	CcSEcCtD
Mirabegron—Dyspepsia—Prednisone—multiple sclerosis	0.00011	0.00145	CcSEcCtD
Mirabegron—Arthralgia—Methotrexate—multiple sclerosis	0.000109	0.00144	CcSEcCtD
Mirabegron—Rash—Prednisolone—multiple sclerosis	0.000108	0.00143	CcSEcCtD
Mirabegron—Dermatitis—Prednisolone—multiple sclerosis	0.000108	0.00143	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000108	0.00143	CcSEcCtD
Mirabegron—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000108	0.00142	CcSEcCtD
Mirabegron—Fatigue—Prednisone—multiple sclerosis	0.000108	0.00142	CcSEcCtD
Mirabegron—Headache—Prednisolone—multiple sclerosis	0.000108	0.00142	CcSEcCtD
Mirabegron—Constipation—Prednisone—multiple sclerosis	0.000107	0.00141	CcSEcCtD
Mirabegron—Dizziness—Triamcinolone—multiple sclerosis	0.000105	0.00138	CcSEcCtD
Mirabegron—Dizziness—Methylprednisolone—multiple sclerosis	0.000104	0.00138	CcSEcCtD
Mirabegron—Infection—Methotrexate—multiple sclerosis	0.000104	0.00137	CcSEcCtD
Mirabegron—Asthenia—Betamethasone—multiple sclerosis	0.000103	0.00136	CcSEcCtD
Mirabegron—Asthenia—Dexamethasone—multiple sclerosis	0.000103	0.00136	CcSEcCtD
Mirabegron—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000102	0.00135	CcSEcCtD
Mirabegron—Nausea—Prednisolone—multiple sclerosis	0.000102	0.00135	CcSEcCtD
Mirabegron—Pruritus—Betamethasone—multiple sclerosis	0.000101	0.00134	CcSEcCtD
Mirabegron—Pruritus—Dexamethasone—multiple sclerosis	0.000101	0.00134	CcSEcCtD
Mirabegron—Skin disorder—Methotrexate—multiple sclerosis	0.000101	0.00134	CcSEcCtD
Mirabegron—Rash—Triamcinolone—multiple sclerosis	9.97e-05	0.00131	CcSEcCtD
Mirabegron—Dermatitis—Triamcinolone—multiple sclerosis	9.96e-05	0.00131	CcSEcCtD
Mirabegron—Rash—Methylprednisolone—multiple sclerosis	9.94e-05	0.00131	CcSEcCtD
Mirabegron—Dermatitis—Methylprednisolone—multiple sclerosis	9.93e-05	0.00131	CcSEcCtD
Mirabegron—Urticaria—Prednisone—multiple sclerosis	9.92e-05	0.00131	CcSEcCtD
Mirabegron—Headache—Triamcinolone—multiple sclerosis	9.9e-05	0.00131	CcSEcCtD
Mirabegron—Headache—Methylprednisolone—multiple sclerosis	9.88e-05	0.0013	CcSEcCtD
Mirabegron—Abdominal pain—Prednisone—multiple sclerosis	9.87e-05	0.0013	CcSEcCtD
Mirabegron—Diarrhoea—Dexamethasone—multiple sclerosis	9.81e-05	0.00129	CcSEcCtD
Mirabegron—Diarrhoea—Betamethasone—multiple sclerosis	9.81e-05	0.00129	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	9.51e-05	0.00125	CcSEcCtD
Mirabegron—Dizziness—Betamethasone—multiple sclerosis	9.48e-05	0.00125	CcSEcCtD
Mirabegron—Dizziness—Dexamethasone—multiple sclerosis	9.48e-05	0.00125	CcSEcCtD
Mirabegron—Nausea—Triamcinolone—multiple sclerosis	9.39e-05	0.00124	CcSEcCtD
Mirabegron—Nausea—Methylprednisolone—multiple sclerosis	9.37e-05	0.00124	CcSEcCtD
Mirabegron—Dyspepsia—Methotrexate—multiple sclerosis	9.19e-05	0.00121	CcSEcCtD
Mirabegron—Rash—Betamethasone—multiple sclerosis	9.04e-05	0.00119	CcSEcCtD
Mirabegron—Rash—Dexamethasone—multiple sclerosis	9.04e-05	0.00119	CcSEcCtD
Mirabegron—Dermatitis—Dexamethasone—multiple sclerosis	9.03e-05	0.00119	CcSEcCtD
Mirabegron—Dermatitis—Betamethasone—multiple sclerosis	9.03e-05	0.00119	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Methotrexate—multiple sclerosis	9.01e-05	0.00119	CcSEcCtD
Mirabegron—Fatigue—Methotrexate—multiple sclerosis	9e-05	0.00119	CcSEcCtD
Mirabegron—Headache—Dexamethasone—multiple sclerosis	8.98e-05	0.00119	CcSEcCtD
Mirabegron—Headache—Betamethasone—multiple sclerosis	8.98e-05	0.00119	CcSEcCtD
Mirabegron—Asthenia—Prednisone—multiple sclerosis	8.96e-05	0.00118	CcSEcCtD
Mirabegron—Pruritus—Prednisone—multiple sclerosis	8.84e-05	0.00117	CcSEcCtD
Mirabegron—Diarrhoea—Prednisone—multiple sclerosis	8.55e-05	0.00113	CcSEcCtD
Mirabegron—Gastrointestinal pain—Methotrexate—multiple sclerosis	8.54e-05	0.00113	CcSEcCtD
Mirabegron—Nausea—Dexamethasone—multiple sclerosis	8.52e-05	0.00112	CcSEcCtD
Mirabegron—Nausea—Betamethasone—multiple sclerosis	8.52e-05	0.00112	CcSEcCtD
Mirabegron—Urticaria—Methotrexate—multiple sclerosis	8.29e-05	0.00109	CcSEcCtD
Mirabegron—Dizziness—Prednisone—multiple sclerosis	8.26e-05	0.00109	CcSEcCtD
Mirabegron—Abdominal pain—Methotrexate—multiple sclerosis	8.25e-05	0.00109	CcSEcCtD
Mirabegron—Rash—Prednisone—multiple sclerosis	7.88e-05	0.00104	CcSEcCtD
Mirabegron—Dermatitis—Prednisone—multiple sclerosis	7.87e-05	0.00104	CcSEcCtD
Mirabegron—Headache—Prednisone—multiple sclerosis	7.82e-05	0.00103	CcSEcCtD
Mirabegron—Asthenia—Methotrexate—multiple sclerosis	7.49e-05	0.000988	CcSEcCtD
Mirabegron—Nausea—Prednisone—multiple sclerosis	7.42e-05	0.000979	CcSEcCtD
Mirabegron—Pruritus—Methotrexate—multiple sclerosis	7.39e-05	0.000974	CcSEcCtD
Mirabegron—Diarrhoea—Methotrexate—multiple sclerosis	7.14e-05	0.000942	CcSEcCtD
Mirabegron—Dizziness—Methotrexate—multiple sclerosis	6.9e-05	0.00091	CcSEcCtD
Mirabegron—Rash—Methotrexate—multiple sclerosis	6.58e-05	0.000868	CcSEcCtD
Mirabegron—Dermatitis—Methotrexate—multiple sclerosis	6.58e-05	0.000867	CcSEcCtD
Mirabegron—Headache—Methotrexate—multiple sclerosis	6.54e-05	0.000863	CcSEcCtD
Mirabegron—Nausea—Methotrexate—multiple sclerosis	6.2e-05	0.000818	CcSEcCtD
Mirabegron—ALB—Vitamin B12 Metabolism—APOE—multiple sclerosis	2.61e-05	0.00398	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	2.6e-05	0.00396	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	2.6e-05	0.00396	CbGpPWpGaD
Mirabegron—ABCB1—Allograft Rejection—CD40—multiple sclerosis	2.56e-05	0.00389	CbGpPWpGaD
Mirabegron—ABCB1—Allograft Rejection—CTLA4—multiple sclerosis	2.52e-05	0.00384	CbGpPWpGaD
Mirabegron—ALB—Platelet activation, signaling and aggregation—PLEK—multiple sclerosis	2.52e-05	0.00383	CbGpPWpGaD
Mirabegron—ALB—Folate Metabolism—IL4—multiple sclerosis	2.51e-05	0.00383	CbGpPWpGaD
Mirabegron—ADRB3—GPCR ligand binding—CCL3—multiple sclerosis	2.5e-05	0.0038	CbGpPWpGaD
Mirabegron—ADRB3—Class A/1 (Rhodopsin-like receptors)—CXCL10—multiple sclerosis	2.46e-05	0.00375	CbGpPWpGaD
Mirabegron—ALB—Vitamin B12 Metabolism—ICAM1—multiple sclerosis	2.45e-05	0.00374	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—S1PR1—multiple sclerosis	2.44e-05	0.00371	CbGpPWpGaD
Mirabegron—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	2.44e-05	0.00371	CbGpPWpGaD
Mirabegron—ADRB3—GPCR ligand binding—PTGER4—multiple sclerosis	2.4e-05	0.00366	CbGpPWpGaD
Mirabegron—ADRB3—GPCR ligand binding—CXCR3—multiple sclerosis	2.32e-05	0.00353	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—RRM1—multiple sclerosis	2.3e-05	0.00351	CbGpPWpGaD
Mirabegron—SLCO1A2—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	2.3e-05	0.0035	CbGpPWpGaD
Mirabegron—ADRB3—GPCR downstream signaling—RGS1—multiple sclerosis	2.28e-05	0.00348	CbGpPWpGaD
Mirabegron—ADRB3—GPCR ligand binding—CCR2—multiple sclerosis	2.26e-05	0.00344	CbGpPWpGaD
Mirabegron—ADRB3—GPCRs, Class A Rhodopsin-like—CCR5—multiple sclerosis	2.23e-05	0.00339	CbGpPWpGaD
Mirabegron—ABCB1—Allograft Rejection—HLA-DQA1—multiple sclerosis	2.22e-05	0.00338	CbGpPWpGaD
Mirabegron—ALB—SLC-mediated transmembrane transport—SLC30A7—multiple sclerosis	2.21e-05	0.00336	CbGpPWpGaD
Mirabegron—ALB—Vitamin B12 Metabolism—CCL2—multiple sclerosis	2.2e-05	0.00334	CbGpPWpGaD
Mirabegron—ADRB3—GPCR downstream signaling—GPR65—multiple sclerosis	2.16e-05	0.0033	CbGpPWpGaD
Mirabegron—ADRB3—Class A/1 (Rhodopsin-like receptors)—CCL5—multiple sclerosis	2.12e-05	0.00323	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—MERTK—multiple sclerosis	2.1e-05	0.0032	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—SELPLG—multiple sclerosis	2.1e-05	0.0032	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—CD58—multiple sclerosis	2.1e-05	0.0032	CbGpPWpGaD
Mirabegron—ADRB3—GPCR ligand binding—CNR1—multiple sclerosis	2.08e-05	0.00317	CbGpPWpGaD
Mirabegron—ABCB1—Allograft Rejection—HLA-DQB1—multiple sclerosis	2.08e-05	0.00316	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—RGS1—multiple sclerosis	2.07e-05	0.00316	CbGpPWpGaD
Mirabegron—CYP3A4—Biological oxidations—CYP27B1—multiple sclerosis	2.04e-05	0.0031	CbGpPWpGaD
Mirabegron—CYP3A4—Biological oxidations—CYP24A1—multiple sclerosis	2.04e-05	0.0031	CbGpPWpGaD
Mirabegron—CYP3A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	2.01e-05	0.00306	CbGpPWpGaD
Mirabegron—CYP3A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	2.01e-05	0.00306	CbGpPWpGaD
Mirabegron—ABCB1—Allograft Rejection—CD86—multiple sclerosis	2e-05	0.00304	CbGpPWpGaD
Mirabegron—ALB—Folate Metabolism—ICAM1—multiple sclerosis	2e-05	0.00304	CbGpPWpGaD
Mirabegron—ADRB3—GPCR downstream signaling—CXCL13—multiple sclerosis	1.98e-05	0.00301	CbGpPWpGaD
Mirabegron—ADRB3—GPCR downstream signaling—CCR1—multiple sclerosis	1.98e-05	0.00301	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—GPR65—multiple sclerosis	1.96e-05	0.00299	CbGpPWpGaD
Mirabegron—ABCB1—Allograft Rejection—CD40LG—multiple sclerosis	1.96e-05	0.00298	CbGpPWpGaD
Mirabegron—ABCB1—Allograft Rejection—IL10—multiple sclerosis	1.96e-05	0.00298	CbGpPWpGaD
Mirabegron—ADRB3—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	1.91e-05	0.00291	CbGpPWpGaD
Mirabegron—ABCB1—Allograft Rejection—IL4—multiple sclerosis	1.91e-05	0.0029	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—LINGO1—multiple sclerosis	1.9e-05	0.00289	CbGpPWpGaD
Mirabegron—ADRB3—GPCR ligand binding—CXCL10—multiple sclerosis	1.88e-05	0.00286	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—SRM—multiple sclerosis	1.87e-05	0.00285	CbGpPWpGaD
Mirabegron—ALB—Vitamin B12 Metabolism—IFNG—multiple sclerosis	1.87e-05	0.00284	CbGpPWpGaD
Mirabegron—ABCB1—Allograft Rejection—HLA-B—multiple sclerosis	1.86e-05	0.00284	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of proteins—SLC30A7—multiple sclerosis	1.83e-05	0.00279	CbGpPWpGaD
Mirabegron—SLCO1A2—Transmembrane transport of small molecules—AQP4—multiple sclerosis	1.82e-05	0.00277	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—CCR1—multiple sclerosis	1.8e-05	0.00274	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—CXCL13—multiple sclerosis	1.8e-05	0.00274	CbGpPWpGaD
Mirabegron—ALB—Folate Metabolism—CCL2—multiple sclerosis	1.79e-05	0.00272	CbGpPWpGaD
Mirabegron—ABCB1—Allograft Rejection—FAS—multiple sclerosis	1.76e-05	0.00268	CbGpPWpGaD
Mirabegron—ABCB1—Allograft Rejection—IL2RA—multiple sclerosis	1.75e-05	0.00266	CbGpPWpGaD
Mirabegron—ABCB1—Allograft Rejection—HLA-A—multiple sclerosis	1.73e-05	0.00263	CbGpPWpGaD
Mirabegron—ALB—Vitamin B12 Metabolism—IL1B—multiple sclerosis	1.67e-05	0.00254	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—TAGAP—multiple sclerosis	1.65e-05	0.00251	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—SRM—multiple sclerosis	1.64e-05	0.0025	CbGpPWpGaD
Mirabegron—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	1.63e-05	0.00248	CbGpPWpGaD
Mirabegron—ADRB3—GPCR ligand binding—CCL5—multiple sclerosis	1.61e-05	0.00246	CbGpPWpGaD
Mirabegron—SLCO1A2—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	1.61e-05	0.00245	CbGpPWpGaD
Mirabegron—ALB—Selenium Micronutrient Network—ICAM1—multiple sclerosis	1.59e-05	0.00241	CbGpPWpGaD
Mirabegron—ABCB1—Allograft Rejection—HLA-DRB1—multiple sclerosis	1.58e-05	0.0024	CbGpPWpGaD
Mirabegron—ALB—SLC-mediated transmembrane transport—SLC11A1—multiple sclerosis	1.54e-05	0.00235	CbGpPWpGaD
Mirabegron—ALB—Folate Metabolism—IFNG—multiple sclerosis	1.52e-05	0.00231	CbGpPWpGaD
Mirabegron—ADRB3—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	1.49e-05	0.00227	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of proteins—PABPC1—multiple sclerosis	1.48e-05	0.00226	CbGpPWpGaD
Mirabegron—ALB—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	1.48e-05	0.00226	CbGpPWpGaD
Mirabegron—ADRB3—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	1.46e-05	0.00222	CbGpPWpGaD
Mirabegron—ABCB1—Allograft Rejection—CD80—multiple sclerosis	1.46e-05	0.00222	CbGpPWpGaD
Mirabegron—ADRB3—GPCR ligand binding—CCR5—multiple sclerosis	1.45e-05	0.00221	CbGpPWpGaD
Mirabegron—ALB—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	1.45e-05	0.00221	CbGpPWpGaD
Mirabegron—ALB—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	1.45e-05	0.00221	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—S1PR1—multiple sclerosis	1.44e-05	0.00219	CbGpPWpGaD
Mirabegron—ALB—Selenium Micronutrient Network—CCL2—multiple sclerosis	1.42e-05	0.00216	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—GPC5—multiple sclerosis	1.4e-05	0.00213	CbGpPWpGaD
Mirabegron—ADRB3—GPCR downstream signaling—PTGER4—multiple sclerosis	1.36e-05	0.00207	CbGpPWpGaD
Mirabegron—ALB—Folate Metabolism—IL1B—multiple sclerosis	1.35e-05	0.00206	CbGpPWpGaD
Mirabegron—ALB—Folate Metabolism—IL2—multiple sclerosis	1.35e-05	0.00206	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of proteins—RPL5—multiple sclerosis	1.34e-05	0.00204	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—CYP24A1—multiple sclerosis	1.32e-05	0.00201	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—CYP27B1—multiple sclerosis	1.32e-05	0.00201	CbGpPWpGaD
Mirabegron—CYP2D6—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	1.32e-05	0.00201	CbGpPWpGaD
Mirabegron—ADRB3—GPCR downstream signaling—CXCR3—multiple sclerosis	1.31e-05	0.002	CbGpPWpGaD
Mirabegron—ABCB1—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	1.3e-05	0.00198	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—PLEK—multiple sclerosis	1.3e-05	0.00198	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	1.29e-05	0.00197	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—CCL3—multiple sclerosis	1.28e-05	0.00195	CbGpPWpGaD
Mirabegron—ADRB3—GPCR downstream signaling—CCR2—multiple sclerosis	1.28e-05	0.00194	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	1.26e-05	0.00192	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—PTGER4—multiple sclerosis	1.23e-05	0.00188	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—RGS1—multiple sclerosis	1.22e-05	0.00186	CbGpPWpGaD
Mirabegron—ALB—Vitamin B12 Metabolism—TNF—multiple sclerosis	1.21e-05	0.00184	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—GPC5—multiple sclerosis	1.21e-05	0.00184	CbGpPWpGaD
Mirabegron—ALB—Selenium Micronutrient Network—IFNG—multiple sclerosis	1.21e-05	0.00184	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—CXCR3—multiple sclerosis	1.19e-05	0.00181	CbGpPWpGaD
Mirabegron—ADRB3—GPCR downstream signaling—CNR1—multiple sclerosis	1.18e-05	0.00179	CbGpPWpGaD
Mirabegron—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—multiple sclerosis	1.17e-05	0.00179	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—GPR65—multiple sclerosis	1.16e-05	0.00177	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—CYP27B1—multiple sclerosis	1.16e-05	0.00176	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—CYP24A1—multiple sclerosis	1.16e-05	0.00176	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—CCR2—multiple sclerosis	1.16e-05	0.00176	CbGpPWpGaD
Mirabegron—ABCB1—Allograft Rejection—IFNG—multiple sclerosis	1.15e-05	0.00176	CbGpPWpGaD
Mirabegron—SLCO1A2—SLC-mediated transmembrane transport—ALB—multiple sclerosis	1.14e-05	0.00173	CbGpPWpGaD
Mirabegron—ADRB3—GPCR ligand binding—POMC—multiple sclerosis	1.14e-05	0.00173	CbGpPWpGaD
Mirabegron—ALB—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	1.12e-05	0.00171	CbGpPWpGaD
Mirabegron—ADRB3—GPCR ligand binding—CCL2—multiple sclerosis	1.11e-05	0.00169	CbGpPWpGaD
Mirabegron—ALB—Selenium Micronutrient Network—IL1B—multiple sclerosis	1.08e-05	0.00164	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—CNR1—multiple sclerosis	1.07e-05	0.00163	CbGpPWpGaD
Mirabegron—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	1.06e-05	0.00162	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—CXCL13—multiple sclerosis	1.06e-05	0.00162	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—CCR1—multiple sclerosis	1.06e-05	0.00162	CbGpPWpGaD
Mirabegron—ADRB3—GPCR downstream signaling—CXCL10—multiple sclerosis	1.06e-05	0.00161	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—GPC5—multiple sclerosis	1.06e-05	0.00161	CbGpPWpGaD
Mirabegron—ABCB1—Allograft Rejection—IL1B—multiple sclerosis	1.03e-05	0.00157	CbGpPWpGaD
Mirabegron—ABCB1—Allograft Rejection—IL2—multiple sclerosis	1.02e-05	0.00156	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	1.01e-05	0.00154	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—RRM1—multiple sclerosis	1e-05	0.00152	CbGpPWpGaD
Mirabegron—ABCB1—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	9.84e-06	0.0015	CbGpPWpGaD
Mirabegron—ALB—Folate Metabolism—TNF—multiple sclerosis	9.83e-06	0.0015	CbGpPWpGaD
Mirabegron—ALB—Vitamin B12 Metabolism—IL6—multiple sclerosis	9.75e-06	0.00148	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—CXCL10—multiple sclerosis	9.62e-06	0.00147	CbGpPWpGaD
Mirabegron—ALB—Metabolism—SRM—multiple sclerosis	9.16e-06	0.00139	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—SELE—multiple sclerosis	9.14e-06	0.00139	CbGpPWpGaD
Mirabegron—ADRB3—GPCR downstream signaling—CCL5—multiple sclerosis	9.12e-06	0.00139	CbGpPWpGaD
Mirabegron—ALB—Platelet degranulation—TGFB1—multiple sclerosis	9.03e-06	0.00137	CbGpPWpGaD
Mirabegron—ALB—Transmembrane transport of small molecules—AQP4—multiple sclerosis	8.87e-06	0.00135	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—RRM1—multiple sclerosis	8.78e-06	0.00134	CbGpPWpGaD
Mirabegron—ALB—Platelet activation, signaling and aggregation—IL2RA—multiple sclerosis	8.76e-06	0.00133	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	8.67e-06	0.00132	CbGpPWpGaD
Mirabegron—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	8.62e-06	0.00131	CbGpPWpGaD
Mirabegron—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—multiple sclerosis	8.6e-06	0.00131	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—CCL5—multiple sclerosis	8.28e-06	0.00126	CbGpPWpGaD
Mirabegron—ADRB3—GPCR downstream signaling—CCR5—multiple sclerosis	8.22e-06	0.00125	CbGpPWpGaD
Mirabegron—ADRB3—GPCR downstream signaling—IL2RA—multiple sclerosis	8.1e-06	0.00123	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—SRM—multiple sclerosis	8.02e-06	0.00122	CbGpPWpGaD
Mirabegron—ABCB1—Allograft Rejection—TGFB1—multiple sclerosis	7.99e-06	0.00122	CbGpPWpGaD
Mirabegron—ALB—Folate Metabolism—IL6—multiple sclerosis	7.93e-06	0.00121	CbGpPWpGaD
Mirabegron—ALB—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	7.85e-06	0.00119	CbGpPWpGaD
Mirabegron—ALB—Selenium Micronutrient Network—TNF—multiple sclerosis	7.81e-06	0.00119	CbGpPWpGaD
Mirabegron—ABCB1—Transmembrane transport of small molecules—AQP4—multiple sclerosis	7.78e-06	0.00118	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	7.76e-06	0.00118	CbGpPWpGaD
Mirabegron—BCHE—Transmission across Chemical Synapses—MAPK1—multiple sclerosis	7.64e-06	0.00116	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—CCL3—multiple sclerosis	7.56e-06	0.00115	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—SRM—multiple sclerosis	7.56e-06	0.00115	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—CCR5—multiple sclerosis	7.46e-06	0.00114	CbGpPWpGaD
Mirabegron—ABCB1—Allograft Rejection—TNF—multiple sclerosis	7.46e-06	0.00114	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—IL2RA—multiple sclerosis	7.35e-06	0.00112	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—PTGER4—multiple sclerosis	7.28e-06	0.00111	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—PGR—multiple sclerosis	7.17e-06	0.00109	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—CXCR3—multiple sclerosis	7.03e-06	0.00107	CbGpPWpGaD
Mirabegron—CYP2D6—Biological oxidations—POMC—multiple sclerosis	7.01e-06	0.00107	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—CD28—multiple sclerosis	6.97e-06	0.00106	CbGpPWpGaD
Mirabegron—ABCB1—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	6.87e-06	0.00105	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—CCR2—multiple sclerosis	6.84e-06	0.00104	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	6.81e-06	0.00104	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	6.67e-06	0.00102	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—ITGA4—multiple sclerosis	6.61e-06	0.00101	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—IFNB1—multiple sclerosis	6.56e-06	0.000999	CbGpPWpGaD
Mirabegron—ALB—Metabolism—CYP24A1—multiple sclerosis	6.45e-06	0.000982	CbGpPWpGaD
Mirabegron—ALB—Metabolism—CYP27B1—multiple sclerosis	6.45e-06	0.000982	CbGpPWpGaD
Mirabegron—ADRB3—GPCR downstream signaling—POMC—multiple sclerosis	6.42e-06	0.000978	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—CNR1—multiple sclerosis	6.31e-06	0.000961	CbGpPWpGaD
Mirabegron—ALB—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	6.3e-06	0.00096	CbGpPWpGaD
Mirabegron—ALB—Selenium Micronutrient Network—IL6—multiple sclerosis	6.3e-06	0.00096	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	6.08e-06	0.000926	CbGpPWpGaD
Mirabegron—ALB—Metabolism—GPC5—multiple sclerosis	5.9e-06	0.000898	CbGpPWpGaD
Mirabegron—BCHE—Neuronal System—MAPK1—multiple sclerosis	5.85e-06	0.000891	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	5.85e-06	0.000891	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—POMC—multiple sclerosis	5.83e-06	0.000888	CbGpPWpGaD
Mirabegron—SLCO1A2—Transmembrane transport of small molecules—ALB—multiple sclerosis	5.78e-06	0.00088	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—BCHE—multiple sclerosis	5.75e-06	0.000875	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—CCL2—multiple sclerosis	5.71e-06	0.000869	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—CXCL10—multiple sclerosis	5.68e-06	0.000866	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—CYP27B1—multiple sclerosis	5.65e-06	0.000861	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—CYP24A1—multiple sclerosis	5.65e-06	0.000861	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	5.33e-06	0.000812	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—CYP27B1—multiple sclerosis	5.33e-06	0.000811	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—CYP24A1—multiple sclerosis	5.33e-06	0.000811	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—TYK2—multiple sclerosis	5.18e-06	0.000789	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—GPC5—multiple sclerosis	5.17e-06	0.000787	CbGpPWpGaD
Mirabegron—ALB—Platelet activation, signaling and aggregation—IL2—multiple sclerosis	5.13e-06	0.000782	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of proteins—POMC—multiple sclerosis	5.06e-06	0.00077	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—CD86—multiple sclerosis	4.97e-06	0.000757	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of proteins—CCL2—multiple sclerosis	4.95e-06	0.000753	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—SRM—multiple sclerosis	4.94e-06	0.000753	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—CCL5—multiple sclerosis	4.89e-06	0.000745	CbGpPWpGaD
Mirabegron—ALB—Metabolism—RRM1—multiple sclerosis	4.89e-06	0.000744	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—GPC5—multiple sclerosis	4.87e-06	0.000742	CbGpPWpGaD
Mirabegron—ADRB3—GPCR downstream signaling—IL2—multiple sclerosis	4.75e-06	0.000723	CbGpPWpGaD
Mirabegron—CYP3A4—Biological oxidations—POMC—multiple sclerosis	4.58e-06	0.000698	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—SPP1—multiple sclerosis	4.53e-06	0.00069	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—IL2RA—multiple sclerosis	4.51e-06	0.000687	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—CCR5—multiple sclerosis	4.41e-06	0.000671	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—IL2RA—multiple sclerosis	4.34e-06	0.000662	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—IL2—multiple sclerosis	4.31e-06	0.000657	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—RRM1—multiple sclerosis	4.28e-06	0.000652	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—RRM1—multiple sclerosis	4.04e-06	0.000615	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—APOE—multiple sclerosis	4.01e-06	0.000611	CbGpPWpGaD
Mirabegron—ALB—Platelet activation, signaling and aggregation—TGFB1—multiple sclerosis	4e-06	0.00061	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	3.95e-06	0.000602	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	3.94e-06	0.0006	CbGpPWpGaD
Mirabegron—ALB—Platelet activation, signaling and aggregation—MAPK1—multiple sclerosis	3.93e-06	0.000598	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	3.87e-06	0.000589	CbGpPWpGaD
Mirabegron—ALB—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	3.79e-06	0.000578	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	3.68e-06	0.000561	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—CD80—multiple sclerosis	3.63e-06	0.000552	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	3.48e-06	0.00053	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	3.48e-06	0.00053	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—APOE—multiple sclerosis	3.46e-06	0.000526	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—POMC—multiple sclerosis	3.45e-06	0.000525	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—CCL2—multiple sclerosis	3.37e-06	0.000513	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—MAPK1—multiple sclerosis	3.3e-06	0.000502	CbGpPWpGaD
Mirabegron—ALB—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	3.26e-06	0.000496	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—GPC5—multiple sclerosis	3.18e-06	0.000485	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—TYK2—multiple sclerosis	3.06e-06	0.000466	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—APOE—multiple sclerosis	3.03e-06	0.000462	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—POMC—multiple sclerosis	2.97e-06	0.000452	CbGpPWpGaD
Mirabegron—ALB—Metabolism—BCHE—multiple sclerosis	2.81e-06	0.000428	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—ALB—multiple sclerosis	2.71e-06	0.000412	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—IL2—multiple sclerosis	2.65e-06	0.000403	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—RRM1—multiple sclerosis	2.64e-06	0.000402	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—POMC—multiple sclerosis	2.61e-06	0.000397	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—IL2—multiple sclerosis	2.55e-06	0.000388	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—IL6—multiple sclerosis	2.53e-06	0.000386	CbGpPWpGaD
Mirabegron—ABCB1—Transmembrane transport of small molecules—ALB—multiple sclerosis	2.47e-06	0.000377	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—BCHE—multiple sclerosis	2.46e-06	0.000375	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—MMP9—multiple sclerosis	2.41e-06	0.000367	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—ALB—multiple sclerosis	2.38e-06	0.000362	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—BCHE—multiple sclerosis	2.32e-06	0.000353	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—STAT3—multiple sclerosis	2.14e-06	0.000326	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—TGFB1—multiple sclerosis	2.06e-06	0.000314	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—MAPK1—multiple sclerosis	2.02e-06	0.000308	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—MYC—multiple sclerosis	1.99e-06	0.000303	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—TGFB1—multiple sclerosis	1.99e-06	0.000303	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—MAPK1—multiple sclerosis	1.95e-06	0.000297	CbGpPWpGaD
Mirabegron—ALB—Metabolism—APOE—multiple sclerosis	1.69e-06	0.000257	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—BCHE—multiple sclerosis	1.52e-06	0.000231	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—IL6—multiple sclerosis	1.5e-06	0.000228	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—APOE—multiple sclerosis	1.48e-06	0.000225	CbGpPWpGaD
Mirabegron—ALB—Metabolism—POMC—multiple sclerosis	1.45e-06	0.000221	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—APOE—multiple sclerosis	1.39e-06	0.000212	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—POMC—multiple sclerosis	1.27e-06	0.000194	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—POMC—multiple sclerosis	1.2e-06	0.000182	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—ALB—multiple sclerosis	1.16e-06	0.000177	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—ALB—multiple sclerosis	1.09e-06	0.000166	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—APOE—multiple sclerosis	9.12e-07	0.000139	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—POMC—multiple sclerosis	7.83e-07	0.000119	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—ALB—multiple sclerosis	7.14e-07	0.000109	CbGpPWpGaD
